Andromeda Phase III Trial Costs Weigh on Andromeda Results

IDB Holding Corp. Ltd. (TASE:IDBH) subsidiary Clal Biotechnology Industries Ltd. (TASE: CBI) today published its financial report for the second quarter of 2007. The company posted a net loss of NIS 10.3 million on NIS 8.1 million revenue. The second quarter loss was almost double the NIS 5.7 million loss for the corresponding quarter.

MORE ON THIS TOPIC